Responses
Clinical/translational cancer immunotherapy
Original research
Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer
Compose a Response to This Article
Other responses
No responses have been published for this article.